Evidence map›Paper›PMID 25103255›Full record

ReviewNature reviews. Drug discovery2014

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.

Samir Mitragotri, Paul A Burke, Robert Langer

Abstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 573 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
573citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

573 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Oligopeptides/DNA Coacervate Droplets as Macromolecular Delivery Microcarriers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article

513 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samir MitragotriDepartment of Chemical Engineering, Center for Bioengineering, University of California, Santa Barbara, California 92106, USA.
Paul A BurkeBurke Bioventures LLC, 277 Broadway, Cambridge, Massachusetts 02139, USA.
Robert LangerDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Orally bioactive exenatie and insulin for type II diabetesR01DK097379 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI MITRAGOTRI, SAMIR S · 2013 to 2016
$1.3M
NIBIB NIH HHS R37 EB000244NIBIB NIH HHS R37‑EB000244NIDDK NIH HHS R01 DK097379NIDDK NIH HHS R01DK097379.
6 · The paper itself

Abstract

The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies and recombinant proteins, poses substantial challenges owing to their large size and susceptibility to degradation. In this Review we highlight recent advances in formulation and delivery strategies--such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs--and discuss their advantages and limitations. We also highlight current and emerging delivery routes that provide an alternative to injection, including transdermal, oral and pulmonary delivery routes. In addition, the potential of targeted and intracellular protein delivery is discussed.

Indexed as

AnimalsBiopharmaceuticsChemistry, PharmaceuticalDrug Delivery SystemsHumans

Identifiers

PMID25103255
PMCPMC4455970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.